Rheumatoid Arthritis (RA) presents a significant medical challenge due to its complex etiology and lack of a definitive cure. Treatment aims to alleviate symptoms and improve quality of life, but accessibility and affordability remain critical considerations. Current therapies include NSAIDs, corticosteroids, and DMARDs, yet limitations such as rapid clearance and systemic toxicity persist. In response, research is exploring innovative drug delivery methods, notably peptide-based nanotherapeutics, offering enhanced stability and targeted drug release.

Peptide-based nanotherapeutics hold promise due to their ability to self-assemble into various nanostructures, streamlining drug delivery processes and improving efficacy. Building on this, my hypothesis proposes that utilizing common glucocorticoids in prodrug form as peptide-drug conjugates, with a cartilage targeting peptide linked to a model drug via a pH responsive bond, will enhance therapeutic efficacy and targeted delivery in RA. This strategy leverages the peptide's targeting capabilities and pH-responsive release mechanism to improve precision, expand therapeutic options, and reduce systemic toxicity, even with systemic administration. This hypothesis underscores the potential of innovative drug delivery approaches to address the complexities of RA treatment and improve patient outcomes.